{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Belgium Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/be/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/be/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from Belgium, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:64a311673a4275110c7f4979ead5a7faed1c0a8ff0cdfc3957387b4cc2c7dea5", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-favor-argenx-argx-183557286.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-favor-argenx-argx-183557286.html", "title": "Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences", "content_text": "argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, to Argenx's immunology pipeline. Both companies' boards have approved the deal, which the companies expect to close in the third quarter of 2026. Why Argenx Needs a Second Act argenx SE (NASDAQ:ARGX) has built its business almost entirely around one blockbuster drug, Vyvgart, which treats several autoimmune diseases and continues to see strong demand. However, analysts expect Vyvgart's growth to peak in the early 2030s. Argenx needs its next act. FB102 has shown early promise in two very different autoimmune conditions, the skin condition vitiligo and celiac disease. Argenx sees potential for it to address multiple autoimmune diseases beyond those. This makes you wonder: will FB102 become the blockbuster that carries Argenx past Vyvgart's eventual peak, or is this a $2.2 billion bet on early-stage data that may not pan out?Hedge Funds Favor Argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences Argenx's Bull and Bear Case Analysts at Van Lanschot Kempen called it \"the right deal at the right time,\" arguing it sets Argenx up for continued growth once Vyvgart's peak passes. KBC Securities analysts separately said FB102 has the potential to become a blockbuster in its own right, fitting well with Argenx's longer-term growth strategy. However, Argenx shares actually fell as much as 0.9% on the announcement before paring the loss, a lukewarm reaction from investors for the buyer. It's also not argenx SE (NASDAQ:ARGX) 's first pipeline stumble. In December, the company's shares dipped after it discontinued late-stage trials of Vyvgart for a separate eye condition, a reminder that pipeline expansion doesn't always pay off. Forte's Bull and Bear Case Forte Biosciences, Inc. (NASDAQ:FBRX) shares soared as much as 42% to $77.86 in premarket trading, essentially matching the offer price, a sign the market is confident this deal will close. The nearly 40% premium and Forte's early trial success in two separate autoimmune conditions show the market recognizing real value in a small, Dallas-based biotech's pipeline. However, as an acquisition target, the $77 a share deal price now caps Forte shareholders' upside. The transaction still needs to clear customary closing conditions before it closes in the third quarter, leaving some execution risk between now and then. Story Continues Insider Monkey's Hedge Fund Data Insider Monkey's hedge fund database shows argenx SE (NASDAQ:ARGX) had 42 hedge fund holders as of Q1 2026, down from 48 the quarter before, while the dollar value hedge funds held in Argenx fell from about $2.33 billion to $1.78 billion, a cooling of hedge fund interest even before this deal. Forte Biosciences, Inc. (NASDAQ:FBRX)had just 23 holders, up from 14, while the dollar value hedge funds held in Forte rose from about $93 million to $129 million, a much smaller but growing hedge fund base typical of a small biotech about to be acquired. Conclusion For Argenx, this is a bet that a small biotech's early data can grow into its next blockbuster before Vyvgart's growth eventually slows. For Forte shareholders, the deal is basically already priced in. While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock. READ NEXT: Hedge Funds Are Bullish on DXC Technology (DXC) and Blackstone Inc. (BX)'s Profit Jumped 26% on AI Bets but the Stock Barely Moved. Here's Why. Disclosure: None. This article is originally published at Ins", "date_published": "2026-08-11T18:35:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ARGX"], "_sharemaestro": {"country": "Belgium", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ARGX", "name": "argenx SE", "sentiment_url": "https://sharemaestro.com/sentiment/f9b4ca3a-d369-4b92-8ef4-dd9fbd09092d/"}]}}, {"id": "source:f7a30a89644c57d89e135fc152fadf8f6cf5fbb9c68c4262eefdd9b7f5f25ba5", "url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-draws-fresh-161353432.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-draws-fresh-161353432.html", "title": "argenx (ENXTBR:ARGX) Draws Fresh Valuation Debate, Is The Stock Overvalued Or Undervalued?", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recent share performance and business profile Without a single clear news event driving headlines, argenx (ENXTBR:ARGX) has still drawn attention after a recent move in its share price and steady gains over the past year. The stock last closed at \u20ac767, with returns around 0.5% over the past day and roughly 6% over the past week. Over the past month the move has been closer to flat, while the past 3 months show a gain of about 9.9%. On a year to date basis the stock is up about 6%, and the 1 year total return sits near 38.6%. argenx is a commercial stage biopharma company focused on treatments for autoimmune diseases, including products such as VYVGART and VYVGART HYTRULO. The company reports revenue of \u20ac5,315.469, with biotechnology as its primary segment, and business spread across the United States, Japan, China and other markets. See our latest analysis for argenx. For context, argenx's recent 6.2% 7 day share price return sits on top of a 1 year total shareholder return of 38.6%. This combination may indicate strengthening momentum as investors reassess its growth profile and risk outlook. If argenx has you looking more closely at healthcare and biotech, this could be a moment to widen your watchlist with the 130 healthcare AI stocks After a 1 year return near 38.6% and a market value around \u20ac47.97b, the key tension for argenx now is simple: is most of the upside already in the price, or not yet reflected in it? Most Popular Narrative: 11.7% Overvalued According to the widely followed argenx narrative from user kapirey, the fair value sits at \u20ac686.43 compared with the recent close at \u20ac767. The narrative builds its case around the existing commercial franchise and a broad autoimmune pipeline. argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases. The investment thesis is based on: \u2022 Leadership in a new therapeutic class (FcRn inhibitors) \u2022 Very strong commercial growth (revenues doubled in 2 years) \u2022 Pipeline with multiple near-term catalysts \u2022 Typical biotech risks: dependence on a single asset, pricing pressure, competition Read the complete narrative. The fair value in this narrative leans heavily on high revenue growth, thick profit margins and a premium future earnings multiple. It is useful to understand which specific growth and margin assumptions sit behind that view and how they connect to argenx's FcRn focus and pipeline breadth. Story Continues Result: Fair Value of \u20ac686.43 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the argenx story still faces real risk if VYVGART concentration remains high, or if key Phase 3 trials and regulatory decisions disappoint expectations. Find out about the key risks to this argenx narrative. Another view on argenx valuation The user narrative suggests argenx looks around 11.7% overvalued at \u20ac767 based on a future earnings multiple. A contrasting signal comes from our DCF model, which points to a fair value near \u20ac1,908.04. That implies the stock trades about 59.8% below this estimate. Which perspective do you think better reflects the risk around VYVGART and the pipeline? Look into how the SWS DCF model arrives at its fair value.ARGX Discounted Cash Flow as at Aug 2026 Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out argenx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 262 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If the split between argenx bull and bear views feels f", "date_published": "2026-08-11T16:13:53+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ARGX"], "_sharemaestro": {"country": "Belgium", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ARGX", "name": "argenx SE", "sentiment_url": "https://sharemaestro.com/sentiment/f9b4ca3a-d369-4b92-8ef4-dd9fbd09092d/"}]}}, {"id": "source:64de25c2f0b03d23ec231b6756b869046803bacae8333fa1a1145a28592467d9", "url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-stock-looks-111149889.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-stock-looks-111149889.html", "title": "argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how much optimism is already reflected in the price. argenx has returned 193.8% over the past five years, which puts extra focus on whether recent gains are backed by enduring fundamentals rather than just momentum. The tender offer to acquire Forte Biosciences may support growth expectations if integration goes well. At the sa", "date_published": "2026-08-11T11:11:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ARGX"], "_sharemaestro": {"country": "Belgium", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ARGX", "name": "argenx SE", "sentiment_url": "https://sharemaestro.com/sentiment/f9b4ca3a-d369-4b92-8ef4-dd9fbd09092d/"}]}}, {"id": "source:957a82cda3c91731886ef567b8344bcbc8a4e3cc89b8b942046f1b3c5d329559", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE5oUFlORkQyeUw2ZDY4SkN2Vi1ZRnp6ekw4Sk9vNnFQN0RJYmpIam8yVDFxRHNaWWNoejUyM2hLS2xiTnJJdHhia1FZdm51S1BaMDFkdW5UTWFCZmVwa2FCMUNFbktkZ3VaN01ualJvMkREZ1VfdlkzQUw0UQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE5oUFlORkQyeUw2ZDY4SkN2Vi1ZRnp6ekw4Sk9vNnFQN0RJYmpIam8yVDFxRHNaWWNoejUyM2hLS2xiTnJJdHhia1FZdm51S1BaMDFkdW5UTWFCZmVwa2FCMUNFbktkZ3VaN01ualJvMkREZ1VfdlkzQUw0UQ?oc=5", "title": "ONWD Pr\u00e9visions - Objectif de prix pour 2027", "content_text": "ONWD Pr\u00e9visions - Objectif de prix pour 2027", "date_published": "2026-06-25T18:10:21+00:00", "authors": [{"name": "TradingView"}], "tags": ["Market update", "ONWD"], "_sharemaestro": {"country": "Belgium", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ONWD", "name": "Onward Medical N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/00f268ff-2613-4338-8480-834f070b8dad/"}]}}, {"id": "source:404f7203d1b8f389dc596f038bba1cc0e0a5bcabd71dd4b32ec307196a4efbca", "url": "https://news.google.com/rss/articles/CBMi-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?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi-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?oc=5", "title": "ONWARD\u00ae Medical organise une t\u00e9l\u00e9conf\u00e9rence pour partager", "content_text": "ONWARD\u00ae Medical organise une t\u00e9l\u00e9conf\u00e9rence pour partager", "date_published": "2024-05-22T07:00:00+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Market update", "ONWD"], "_sharemaestro": {"country": "Belgium", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ONWD", "name": "Onward Medical N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/00f268ff-2613-4338-8480-834f070b8dad/"}]}}, {"id": "source:690941c59903b3178b865d66986652859dfb4bf2d31c5a584dbce1c908e7ed54", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPLWxfSnJadk95VG5hUU5nbndQTDZyUF9ZMzgtMUxiYmhPaWc1TE1JbGJIUjQ1c2M0dy14cFhaUGIzbDVFMUlRNUtMZ3RzaXRlM2pPLU9WX0RKU0FVUW1ZcEVqdFM0ZURaaG5EYWUzZTA0Y1NsX1dDVmZXdEVJR1V6M1c2a1gtUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPLWxfSnJadk95VG5hUU5nbndQTDZyUF9ZMzgtMUxiYmhPaWc1TE1JbGJIUjQ1c2M0dy14cFhaUGIzbDVFMUlRNUtMZ3RzaXRlM2pPLU9WX0RKU0FVUW1ZcEVqdFM0ZURaaG5EYWUzZTA0Y1NsX1dDVmZXdEVJR1V6M1c2a1gtUQ?oc=5", "title": "Onward Medical N.V.: Objectif de Cours et Consensus des Analystes | ONWD | NL0015000HT4", "content_text": "Onward Medical N.V.: Objectif de Cours et Consensus des Analystes | ONWD | NL0015000HT4", "date_published": "2022-04-14T03:33:34+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "ONWD"], "_sharemaestro": {"country": "Belgium", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ONWD", "name": "Onward Medical N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/00f268ff-2613-4338-8480-834f070b8dad/"}]}}, {"id": "source:050034afbb0e1a88d90218075070ce569c8bceb3148e26ed61ac22e63d18e607", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNV3lnZEJnMXFEbmNYS09ZRDFyNXVoZ0xGems2NEwwUXVIbmRudDhwMUIyeHF4c1dRU18ycF9GaXhtZF8zZTVEcUwya1VZR1hDSFp0Y2kxSExKcENlZldIWE9rbDVrU0tHTUNaZzlLc0dEN0kyb2ZfTFgwODZFd2hFeVJEZm9XUXNPSjZyMmpoOA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNV3lnZEJnMXFEbmNYS09ZRDFyNXVoZ0xGems2NEwwUXVIbmRudDhwMUIyeHF4c1dRU18ycF9GaXhtZF8zZTVEcUwya1VZR1hDSFp0Y2kxSExKcENlZldIWE9rbDVrU0tHTUNaZzlLc0dEN0kyb2ZfTFgwODZFd2hFeVJEZm9XUXNPSjZyMmpoOA?oc=5", "title": "Onward Medical N.V.: Graphique de cours statique | ONWD | NL0015000HT4", "content_text": "Onward Medical N.V.: Graphique de cours statique | ONWD | NL0015000HT4", "date_published": "2021-11-01T22:49:51+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "ONWD"], "_sharemaestro": {"country": "Belgium", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ONWD", "name": "Onward Medical N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/00f268ff-2613-4338-8480-834f070b8dad/"}]}}, {"id": "source:ea2951a0ace9652a36a5ca60471cf0734a33af87c99bc0114126ae4fd3df1b31", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5HRklzbl9xQ0VKU0twYXA1TWVpYVRzRU9jY3JDbFU0Vi1HYm12ZFRzLVFWeFlMeHVJeklpOHBFaGsxUjJDYTBsUmo2U0txS1VJWXE0VkhGTy15Q0VEZ0ZYMmh4UHcyN3pudjV2MVA0ODBoNklD?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidEFVX3lxTE5HRklzbl9xQ0VKU0twYXA1TWVpYVRzRU9jY3JDbFU0Vi1HYm12ZFRzLVFWeFlMeHVJeklpOHBFaGsxUjJDYTBsUmo2U0txS1VJWXE0VkhGTy15Q0VEZ0ZYMmh4UHcyN3pudjV2MVA0ODBoNklD?oc=5", "title": "UCB SA: Objectif de Cours et Consensus des Analystes | UCB | BE0003739530", "content_text": "UCB SA: Objectif de Cours et Consensus des Analystes | UCB | BE0003739530", "date_published": "2020-08-28T16:49:41+00:00", "authors": [{"name": "Zonebourse"}], "tags": ["Market update", "UCB"], "_sharemaestro": {"country": "Belgium", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UCB", "name": "UCB SA", "sentiment_url": "https://sharemaestro.com/sentiment/b564e58a-3f24-4f77-9f7d-0fd1d3a104d9/"}]}}, {"id": "source:d0dd0e44059091b3ceb659ad5f88086f6c9018f7e2e24d8c716aa8650cccc9db", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBsU0t0S1Z3M0tVSWREUkkwcGVNU3puSGdhYWg3T0ozNndfNkJUWW1EcEVscmlQbXE5ZzBfVUtBVU9SNlFzcnhnMjhtU2pXYTZf?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFBsU0t0S1Z3M0tVSWREUkkwcGVNU3puSGdhYWg3T0ozNndfNkJUWW1EcEVscmlQbXE5ZzBfVUtBVU9SNlFzcnhnMjhtU2pXYTZf?oc=5", "title": "Le prix de l'action UCB SA (UCB.BR) : Actualit\u00e9s et pr\u00e9visions des analystes", "content_text": "Le prix de l'action UCB SA (UCB.BR) : Actualit\u00e9s et pr\u00e9visions des analystes", "date_published": "2019-10-09T11:48:54+00:00", "authors": [{"name": "eToro"}], "tags": ["Market update", "UCB"], "_sharemaestro": {"country": "Belgium", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "UCB", "name": "UCB SA", "sentiment_url": "https://sharemaestro.com/sentiment/b564e58a-3f24-4f77-9f7d-0fd1d3a104d9/"}]}}]}